Mineralocorticoid Receptor Antagonism by Eplerenone and Arterial Inflammation in HIV: The MIRABELLA HIV Study.

ABSTRACT:

Importance

The risk for atherosclerotic disease is increased 1.5- to 2.0-fold among persons with HIV (PWH). Increased activation of the renin-angiotensin-aldosterone system may contribute to increased arterial inflammation in this population.

Objective

To determine the effects of eplerenone on arterial inflammation among well-treated PWH without known cardiovascular disease (CVD).

Design, setting, and participants

Well-treated PWH who participated in the double-blinded, placebo-controlled, Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV (MIRACLE HIV) study between February 2017 and March 2022 assessing the effects of eplerenone on myocardial perfusion were invited to participate in the Mineralocorticoid Receptor Antagonism By Eplerenone to Lower

SUBMITTER: Srinivasa S 

PROVIDER: S-EPMC10719827 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature